Details of the Drug

General Information of Drug (ID: DMFJGUL)

Drug Name
BI 3011441
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Small molecular drug
Cross-matching ID
TTD ID
DL5UR0

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ERK activator kinase (MEK) TTZCRP3 NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04742556) A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
5 Clinical pipeline report, company report or official report of Roche.
6 Clinical pipeline report, company report or official report of Genentech (2011).
7 MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.